Business Context and Reporting Period
This Form 6-K filing by AC Immune SA covers the results of the Annual Ordinary Shareholders' Meeting held on June 28, 2019. The company is a foreign private issuer based in Lausanne, Switzerland, and files annual reports under Form 20-F.
Key Financial Metrics
The filing references the 2018 financial year results approved by shareholders:
- Net Loss (2018): KCHF 48,894 (approx. CHF 48.9 million).
- Accumulated Loss: The 2018 loss was added to a prior loss brought forward of KCHF 58,426, resulting in a new total accumulated loss of KCHF 107,320.
- Revenue and Cash Flow: The filing text does not provide specific values for revenue, operating cash flow, or liquidity metrics for the period.
Material Changes and Governance Actions
Shareholders approved several material governance and capital actions:
- Board Elections: Douglas Williams was re-elected as Chairman; Martin Velasco as Vice-Chairman. Roy Twyman was elected as a new Board member. All directors were re-elected or elected for terms until the next Ordinary General Meeting.
- Compensation Caps (FY 2019-2020):
- Board Non-Performance Cash: Max CHF 547,000.
- Board Equity Grants: Max CHF 626,000.
- Executive Committee Cash (Base): Max CHF 2,407,000.
- Executive Committee Variable Cash: Max CHF 1,195,000.
- Executive Committee Equity Grants: Max CHF 3,126,000.
- Capital Increase: Approved a conditional capital increase for employee benefit plans. This includes creating share capital up to CHF 70,460 via 3,523,000 new shares and amending articles to increase conditional capital by CHF 27,069.90 (1,353,495 shares).
- Auditor: PricewaterhouseCoopers SA was re-elected for a one-year term.
Guidance, Outlook, and Risks
The filing text does not contain specific management guidance, financial outlook, or detailed risk factors for future periods. It notes that agenda items 9 and 10 were withdrawn by the Board prior to the meeting. The primary focus of the document is the ratification of past financial statements and the approval of governance structures.
Investor Verification Checklist
- Verify the full 2018 Annual Report and IFRS financial statements referenced in Agenda Item 1 for detailed revenue and cash flow data.
- Review the attached Exhibit 99.1 (Presentation) and Exhibit 99.2 (Press Release) for strategic updates not included in this summary.
- Confirm the dilution impact of the approved conditional capital increase of 3,523,000 shares for employee benefit plans.
- Monitor the utilization of the approved compensation caps for the Executive Committee and Board for the 2019-2020 period.